Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-alpha for chronic hepatitis C

Area of Science:

• Immunology
• Endocrinology
• Hepatology

Background:

• Interferon-alpha is a common treatment for chronic hepatitis C virus (HCV) infection.
• Emerging evidence suggests a link between interferon-alpha therapy and thyroid autoimmunity.
• Thyroid dysfunction is a potential concern during interferon-alpha treatment.

Purpose of the Study:

• To investigate the impact of interferon-alpha on thyroid hormones and antithyroid antibodies in patients with chronic hepatitis C.
• To determine if induced antithyroid antibodies correlate with clinically significant thyroid dysfunction.
• To assess the necessity of routine antithyroid antibody monitoring during interferon-alpha therapy.

Main Methods:

• Monthly analysis of thyroid hormones and antithyroid antibodies (anti-TPO, antithyroglobulin, TRAB).
• Study included 53 patients receiving interferon-alpha for chronic active hepatitis C.
• Evaluation of antibody levels and thyroid function status throughout treatment.

Main Results:

• Elevated antithyroid peroxydase antibodies (anti-TPO) were observed in some patients, with transient increases in others.
• Antithyroglobulin antibodies appeared in a subset of patients, all also positive for anti-TPO.
• No significant changes in thyroid-stimulating hormone receptor antibodies (TRAB) were detected.
• Most patients with elevated antithyroid antibodies remained euthyroid.
• One patient developed thyroiditis and thyrotoxicosis despite normal baseline antibody levels.

Conclusions:

• Induction of antithyroid antibodies during interferon-alpha therapy for hepatitis C does not typically indicate clinically relevant thyroid dysfunction.
• Routine monitoring of antithyroid antibodies may not be mandatory for patients undergoing interferon-alpha treatment.
• Further research may be needed to fully elucidate the relationship between interferon-alpha and thyroid autoimmunity.